765. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2415 of 9 June 2026, to clarify whether the figure provided for the number of pharmacy reimbursement claims rejected in each year counts unique claims finally refused or counts error events including claims that were subsequently paid; and the reason the combined total of claims approved and claims rejected exceeds the number …
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions under the heading Medicinal Products.
1,228 questions match, newest first.
766. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2415 of 9 June 2026, in which "claim set to pay or already paid" appears among the top five recorded reasons for claim rejection; to provide and the number of pharmacy reimbursement claims that were initially rejected and subsequently paid in each year from 2020 to date, or to confirm that this is not separately recorded [5106…
767. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2415 of 9 June 2026, whether a formal appeals mechanism exists for rejected pharmacy reimbursement claims; if so, the body responsible for deciding such appeals; and the number of appeals received and the number upheld in each year from 2020 to date. [51064/26]
771. Deputy Cian O'Callaghan asked the Minister for Health to provide an update on the work her Department is doing to progress the pricing and reimbursement application (details supplied) for welireg (belzutifan); and if she will make a statement on the matter. [51110/26]
773. Deputy Denise Mitchell asked the Minister for Health the steps she is taking to ensure that the drug belzutifan is available and accessible to those who need it; and if she will make a statement on the matter. [51144/26]
795. Deputy Albert Dolan asked the Minister for Health if she has engaged with the Minister for Finance regarding the application of VAT to certain vaccines and prescribed medical products; if changes are under consideration; and if she will make a statement on the matter. [51289/26]
818. Deputy Barry Heneghan asked the Minister for Health the current status of the health technology assessment and reimbursement process for the medicine belzutifan for the treatment of eligible patients with Von Hippel-Lindau (VHL) syndrome; the expected timelines for completion of the assessment and any subsequent reimbursement decision; and if she will make a statement on the matter. [51420/26]
819. Deputy Barry Heneghan asked the Minister for Health the steps her Department and the HSE are taking to facilitate timely access to belzutifan for eligible patients with Von Hippel-Lindau (VHL) syndrome, if approved for reimbursement; whether engagement has taken place, or is planned, with clinicians, patient representative organisations and other relevant stakeholders regarding access to this treatment; and if s…
820. Deputy Johnny Mythen asked the Minister for Health if belzutifan will be made be available to people suffering from Von Hippel- Lindau disease; and if she will make a statement on the matter. [51422/26]
833. Deputy Naoise Ó Muirí asked the Minister for Health the status of negotiations regarding belzutifan; whether she will expedite the assessment and approval process; and if she will make a statement on the matter. [51584/26]
834. Deputy Naoise Ó Muirí asked the Minister for Health the review she intends to take of Ireland's system for approving access and funding for new drugs and medical treatments; and if she will make a statement on the matter. [51585/26]
840. Deputy Eamon Scanlon asked the Minister for Health the steps being taken to expedite the assessment and approval of belzutifan for patients with Von Hippel–Lindau (VHL) disease to ensure timely access for eligible patients; if she will engage with clinicians and patient groups regarding barriers to access; and if she will make a statement on the matter. [51615/26]
857. Deputy Ryan O'Meara asked the Minister for Health if a pricing and reimbursement application has been received by the HSE for zolbetuximab (vyloy); and if she will make a statement on the matter. [51755/26]
858. Deputy Ryan O'Meara asked the Minister for Health for an update on the pricing and reimbursement application for omaveloxolone (skyclarys); if the commercial proposal has yet been received from the company; and if she will make a statement on the matter. [51756/26]
517. Deputy Ken O'Flynn asked the Minister for Health further to the HSE's confirmation that no national dataset on returned medicines currently exists, whether the national medicines disposal service under CPA25 will record returned medicines as a defined, structured national dataset; to specify the data fields that dataset will capture; and if she will make a statement on the matter. [50611/26]
518. Deputy Ken O'Flynn asked the Minister for Health whether data on the volume, type and cost of medicines returned under the CPA25 disposal service will be published; the frequency of such publication; the date on which the first such report will issue; and if she will make a statement on the matter. [50612/26]
519. Deputy Ken O'Flynn asked the Minister for Health the confirmed commencement date of the national medicines disposal service under CPA25, given the HSE's statement that the service is due to commence "over the summer" in 2026; and if she will make a statement on the matter. [50613/26]
520. Deputy Ken O'Flynn asked the Minister for Health whether a baseline estimate of the annual cost of unused, expired or otherwise wasted medicines will be established at the commencement of the CPA25 disposal service; the methodology to be applied; and if she will make a statement on the matter. [50614/26]
521. Deputy Ken O'Flynn asked the Minister for Health whether waste-reduction targets will be set on foot of the data collected under the CPA25 disposal service; the office responsible for owning and governing that dataset; whether that dataset features on any HSE risk register or audit plan; and if she will make a statement on the matter. [50615/26]
528. Deputy John McGuinness asked the Minister for Health if she will provide an update on the approval of the drug skyclarys in the reimbursement scheme; if all of the information and costings have been submitted by the supplier; and the indicative date for approval. [50630/26]
548. Deputy Mark Ward asked the Minister for Health if belzutifan will be made available to people with Von Hippel-Lindau disease; the steps being taken to make this therapy available; and if she will make a statement on the matter. [50755/26]
789. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2547 of 9 June 2026, the number of the 12,899 respiratory medicine claims rejected under the PCRS between 2023 and 2026 to date, that remain unpaid following resubmission; the breakdown of this unrecovered figure, by year and, by rejection reason; the steps her Department and the HSE are taking to address the volume of rejecti…
807. Deputy Conor Sheehan asked the Minister for Health when the current review of the core list of medications under the long-term illness scheme will be completed; the way in which a drug can be put forward for consideration under this review; and if she will make a statement on the matter. [49053/26]
825. Deputy Niamh Smyth asked the Minister for Health to review the case of a person (details supplied); if she can provide an update on the drug with regards to the medical card system; and if she will make a statement on the matter. [49199/26]
902. Deputy Conor Sheehan asked the Minister for Health if the NCPE is evaluating the application of mounjaro and wegovy for severe metabolic and endocrine conditions alongside obesity; and if she will make a statement on the matter. [49595/26]